Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series.
Rachna GorbudhunPranav Harshad PatelEve HoppingJoseph DoyleGeorgios GeropoulosVasileios K MavroeidisSacheen KumarRicky H BhogalPublished in: Cancers (2022)
NCR, particularly FOLFIRINOX-based treatment, for BR-PDAC results in higher rates of R0 resection and an increased median DFS and OS, supporting its continued use in this patient group.